Generic drugmakers in China are waiting in the wings for Wegovy patent expiration
China may be the first country where Novo Nordisk loses patent protection for active ingredient semaglutide.
Novo Nordisk is facing growing competition on the attractive Chinese market, where at least 11 generic variants of its diabetes drug Ozempic and weight loss treatment Wegovy are in development, Reuters reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
